MOONLAKE IMMUNO (MLTX)
(Real Time Quote from BATS)
$43.56 USD
+0.50 (1.16%)
Updated Aug 8, 2024 01:16 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
MoonLake Immunotherapeutics (MLTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$74.31 | $104.00 | $55.00 | 72.57% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for MoonLake Immunotherapeutics comes to $74.31. The forecasts range from a low of $55.00 to a high of $104.00. The average price target represents an increase of 72.57% from the last closing price of $43.06.
Analyst Price Targets (13)
Broker Rating
MoonLake Immunotherapeutics currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 80% and 6.67% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 6.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/11/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
6/10/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
5/16/2024 | Cantor Fitzgerald & Co | Prakhar Agrawal | Strong Buy | Strong Buy |
4/2/2024 | Goldman Sachs | Richard Law | Not Available | Hold |
4/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
3/15/2024 | Not Identified | Not Identified | Hold | Hold |
3/11/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
2/26/2024 | LifeSci Capital | Rami Katkhuda | Strong Buy | Strong Buy |
2/15/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
1/7/2024 | BTIG | Julian Harrison | Strong Buy | Strong Buy |
12/8/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
11/15/2023 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 15 |
Average Target Price | $74.31 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | -0.35 |